Stepan Company (SCL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Mar, 2026Executive summary
The annual meeting is scheduled for April 28, 2026, with three directors up for election, an advisory vote on executive compensation, and ratification of the external auditor as key agenda items.
Stockholders can vote by mail, phone, or online, and brokers cannot vote on non-routine matters without instructions.
Proxy materials and annual reports are available online, with a push for electronic delivery to reduce paper use.
Voting matters and shareholder proposals
Proposals include electing three directors for three-year terms, a Say-on-Pay advisory vote, and ratification of Deloitte & Touche LLP as independent auditor for 2026.
Shareholder proposals and director nominations for 2027 must comply with SEC rules and company by-laws, with specific deadlines for submission.
Board of directors and corporate governance
The board is divided into three classes with staggered terms; current nominees bring expertise in chemistry, global business, and company operations.
Board committees (Audit, Compliance, Human Capital and Compensation, Nominating and Corporate Governance) are composed entirely of independent directors.
Annual board and committee performance evaluations are conducted, and board leadership is separated between the Chairman and CEO.
The board emphasizes diversity in tenure, age, gender, and ethnicity, and maintains a Lead Independent Director role.
Latest events from Stepan Company
- Adjusted EBITDA fell 14% as restructuring charges drove a net loss, but free cash flow improved.SCL
Q1 202628 Apr 2026 - 2025 results highlight diversified growth, operational excellence, and a robust innovation pipeline.SCL
Investor presentation28 Apr 2026 - EBITDA grew 6% in 2025; Project Catalyst to drive $100M savings, with H2 2026 margin recovery.SCL
Q4 202511 Apr 2026 - Adjusted EBITDA grew 4% in Q2 2024 despite lower net income and significant one-time expenses.SCL
Q2 20242 Feb 2026 - Q3 net income up 88% to $23.6M, EBITDA up 11%, with strong Surfactants and cost savings.SCL
Q3 202417 Jan 2026 - Net income up 42% and EBITDA up 12% on strong surfactant and specialty growth.SCL
Q1 202524 Dec 2025 - Net income up 25% and adjusted EBITDA rose 4%, with Pasadena facility to boost 2025 growth.SCL
Q4 202423 Dec 2025 - Key votes include director elections, executive pay, auditor ratification, and equity plan expansion.SCL
Proxy Filing1 Dec 2025 - Strategic investments and innovation drive growth in key markets, with renewed segment momentum in 2024.SCL
16th Annual Midwest Ideas Conference23 Nov 2025